v3.26.1
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit (Unaudited) - USD ($)
$ in Thousands
Redeemable Convertible Preferred Stock
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2023 $ 104,634 $ 2 $ 2,838 $ (116,828) $ (113,988)
Balance (in Shares) at Dec. 31, 2023 100,608,468 24,522,046      
Net Loss (30,064) (30,064)
Issuance of common stock warrants 76 76
Issuance of common stock warrants (in shares)      
Stock-based compensation 513 513
Exercise of stock options 47 47
Exercise of stock options (in shares) 266,799      
Balance at Dec. 31, 2024 $ 104,634 $ 2 3,474 (146,892) (143,416)
Balance (in Shares) at Dec. 31, 2024 100,608,468 24,788,845      
Net Loss (2,391) (2,391)
Issuance of common stock warrants 121 121
Stock-based compensation 183 183
Exercise of stock options (in shares) 8,125      
Exercise of common stock warrants 3 3
Balance at Mar. 31, 2025 $ 104,634 $ 2 3,781 (149,283) (145,500)
Balance (in Shares) at Mar. 31, 2025 100,608,468 24,796,970      
Balance at Dec. 31, 2024 $ 104,634 $ 2 3,474 (146,892) (143,416)
Balance (in Shares) at Dec. 31, 2024 100,608,468 24,788,845      
Net Loss (39,671) (39,671)
Issuance of common stock warrants 3,545 3,545
Issuance of common stock warrants (in shares)      
Stock-based compensation 553 553
Exercise Of Preferred Stock Warrant For Series F Redeemable Convertible Preferred Stock Value $ 304
Exercise of preferred stock warrant for Series F redeemable convertible preferred stock (in Shares) 110,000      
Conversion of SAFEs to Series F redeemable convertible preferred stock $ 54,790
Conversion of SAFEs to Series F redeemable convertible preferred stock (in shares) 28,242,363      
Conversion of convertible notes to Series F redeemable convertible preferred stock value $ 31,471
Conversion of convertible notes to Series F redeemable convertible preferred stock (in Shares) 16,211,980      
Exercise of stock options 130 130
Exercise of stock options (in shares) 624,451      
Exercise of common stock warrants $ 1 7 8
Exercise of common stock warrants (in shares) 750,000      
Balance at Dec. 31, 2025 $ 191,199 $ 3 7,709 (186,563) (178,851)
Balance (in Shares) at Dec. 31, 2025 145,182,811 26,163,296      
Net Loss (6,941) (6,941)
Issuance of common stock warrants 2,822 2,822
Issuance of common stock warrants (in shares)   2,639,038      
Stock-based compensation 125 125
Conversion of SAFEs to Series F redeemable convertible preferred stock $ 6,668
Conversion of SAFEs to Series F redeemable convertible preferred stock (in shares) 4,433,411      
Exercise of stock options 100 100
Exercise of stock options (in shares) 639,738      
Exercise of common stock warrants 26 26
Exercise of common stock warrants (in shares)        
Balance at Mar. 31, 2026 $ 197,867 $ 3 $ 10,782 $ (193,504) $ (182,719)
Balance (in Shares) at Mar. 31, 2026 149,616,222 29,442,072